Table 4.

Risk factors for death in patients initiating antiretroviral therapy (ART) during follow-up

		Crude					Adjusted
				95% CI for HR					95% CI for HR
		No.	Hazard ratio	Lower	Upper	p	No.	Hazard ratio	Lower	Upper	p
Health facility	Hospital	578	1.00				463	1.00
	Health center	222	2.12	1.03	4.36	0.042	159	1.94	0.68	5.50	0.213
	Missing	5					183
Age groups	> 5 years	447	1.00				397	1.00
	>1–5 years	223	1.21	0.44	3.32	0.718	185	1.60	0.51	5.05	0.421
	0–1 years	121	4.42	1.88	10.41	0.001	40	12.02	3.50	41.28	<0.001
	Missing	14					183
Gender	Female	401	1.00				305	1.00
	Male	399	2.02	0.94	4.31	0.070	317	1.89	0.70	5.10	0.209
	Missing	5					183
Caretaker	Parents	531	1.00				414	1.00
	Others	233	1.44	0.68	3.08	0.344	208	2.00	0.79	5.06	0.144
	Missing	41					183
WAZ at TS	>–1	121	1.00				89	1.00
	<–1 to > − 4	469	3.06	0.40	23.52	0.283	400	2.07	0.25	17.29	0.501
	< − 4	158	8.67	1.12	67.19	0.039	133	6.39	0.78	52.37	0.084
	Missing	57					183
CD4 at TS	>350	252	1.00				231	1.00
	<350	435	1.93	0.71	5.23	0.197	391	2.69	0.89	8.11	0.078
	Missing	118					183
WHO clinical stage at TS	1, 2	341	1.00				270	1.00
	3	379	1.24	0.53	2.90	0.623	307	1.21	0.42	3.44	0.723
	4	63	4.48	1.67	12.05	0.003	45	2.36	0.58	9.69	0.234

Patients lost to follow-up excluded from analysis.

Significant p-values are marked with bold characters.